Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.

INTRODUCTION Pharmacological inhibition of cardiac potassium channels encoded by hERG (human ether-à-go-go-related gene) is associated with QT interval prolongation and torsades de pointes arrhythmia. Electrophysiological assays of hERG channel inhibition are integral to the safety testing of novel drug candidates. This study was conducted to compare, for the high affinity hERG inhibitors dofetilide and cisapride, hERG blockade between action potential (AP) and conventional (step and step-ramp) screening waveforms. Furthermore, it evaluated dynamic (pulse-by-pulse) protocol-dependence of hERG channel inhibition by these drugs. METHODS Whole-cell patch-clamp recordings were made at 37 degrees C from hERG-expressing HEK 293 cells. Half-maximal inhibitory concentrations (IC(50) values) for I(hERG) blockade were obtained using conventional voltage clamp and action potential clamp, using previously digitised ventricular and Purkinje fibre (PF) AP waveforms. RESULTS A more marked variation in IC(50) values with different command waveforms was observed for cisapride (ranging from 7 to 72 nM) than for dofetilide (ranging from 4 to 15 nM), with higher IC(50)s obtained with AP than step or step-ramp commands. The two drugs differed little from one another in effects on voltage-dependent activation; however, I(hERG) blockade by each drug was initially voltage-dependent, but at steady-state was only voltage-dependent for cisapride. There was comparatively little difference between the two drugs in effects on I(hERG) availability or time constants of development of inactivation. Features of time-dependence of blockade and the use of protocols employing varying rest periods in drug or commands of alternating duration highlighted a pronounced ability of cisapride, but not dofetilide, to dissociate and reassociate from hERG on a pulse-by-pulse basis. DISCUSSION Protocols described here that demonstrated dynamic variation (drug dissociation/reassociation) in hERG channel current blockade at 37 degrees C for cisapride may have future value for investigating drug interactions with the hERG channel. Downloadable digitised ventricular and PF AP waveforms that can be used in AP clamp experiments also accompany this article.

[1]  J. Hancox,et al.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.

[2]  Michael Markert,et al.  Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. , 2004, Journal of pharmacological and toxicological methods.

[3]  G. Gintant Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. , 2000, American journal of physiology. Heart and circulatory physiology.

[4]  J. Hancox,et al.  A method for making rapid changes of superfusate whilst maintaining temperature at 37°C , 1996, Pflügers Archiv.

[5]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[6]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[7]  W. Crumb,et al.  Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. , 2004, Journal of pharmacological sciences.

[8]  J. Hancox,et al.  Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability. , 2008, Pharmacology & therapeutics.

[9]  A. Brown,et al.  Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.

[10]  J. Wigle,et al.  Intracellular K+ Is Required for the Inactivation-Induced High-Affinity Binding of Cisapride to HERG Channels , 2005, Molecular Pharmacology.

[11]  E. Carmeliet Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.

[12]  J. Henney Celecoxib Indicated for FAP , 2000 .

[13]  Jules C Hancox,et al.  Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.

[14]  Haruo Honjo,et al.  Molecular determinants of hERG channel block by terfenadine and cisapride. , 2008, Journal of pharmacological sciences.

[15]  Stanley Nattel,et al.  Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.

[16]  R. Baker,et al.  Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. , 2005, Journal of pharmacological and toxicological methods.

[17]  Hao Wang,et al.  Functional and pharmacological properties of canine ERG potassium channels. , 2003, American journal of physiology. Heart and circulatory physiology.

[18]  T. Toga,et al.  The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. , 2007, Journal of pharmacological sciences.

[19]  T J Campbell,et al.  Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states , 1999, British journal of pharmacology.

[20]  Jiesheng Kang,et al.  Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  Anthony Varghese,et al.  Effects of premature stimulation on HERG K+ channels , 2001, The Journal of physiology.

[22]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[23]  Qiuming Gong,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.

[24]  D. Fedida,et al.  Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay , 2004, Journal of biomolecular screening.

[25]  D. Escande,et al.  Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. , 2001, The Journal of pharmacology and experimental therapeutics.

[26]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Hancox,et al.  hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. , 2006, Biochemical and biophysical research communications.

[28]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[29]  Jamie I Vandenberg,et al.  Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.

[30]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[31]  J. Hancox,et al.  Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs , 2008, British journal of pharmacology.

[32]  A. Camm,et al.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.

[33]  J. Hancox,et al.  Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin , 2007, Biochemical pharmacology.

[34]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[35]  Jules C. Hancox,et al.  The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C , 2005 .

[36]  D. Rampe,et al.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.

[37]  R. Shah,et al.  Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. , 2005, Novartis Foundation symposium.

[38]  A. Brown,et al.  Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.

[39]  Y. Kawabata,et al.  Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. , 2004, European journal of pharmacology.

[40]  J. Hancox,et al.  Lidoflazine is a high affinity blocker of the HERG K(+)channel. , 2004, Journal of molecular and cellular cardiology.

[41]  Todd Wisialowski,et al.  Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.

[42]  Gary A Gintant,et al.  Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. , 2008, Pharmacology & therapeutics.

[43]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[44]  Rui Wang,et al.  Endogenous KV channels in human embryonic kidney (HEK-293) cells , 2002, Molecular and Cellular Biochemistry.

[45]  Martyn P Mahaut-Smith,et al.  Temperature dependence of human ether-a-go-go-related gene K+ currents. , 2006, American journal of physiology. Cell physiology.

[46]  State dependent dissociation of HERG channel inhibitors , 2007 .

[47]  Jules C Hancox,et al.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.

[48]  D. Roden,et al.  IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[50]  G. Gintant,et al.  ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF HUMAN ETHER‐A‐GO‐GO‐RELATED GENE (hERG) CHANNELS , 2006, Clinical and experimental pharmacology & physiology.

[51]  Kaichiro Kamiya,et al.  Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.

[52]  J. Henney New Inhaled Corticosteroid , 2000 .

[53]  Jules C Hancox,et al.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin , 2006, British journal of pharmacology.

[54]  A. Bass,et al.  Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. , 2005, Journal of pharmacological and toxicological methods.

[55]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[56]  Harry J. Witchel,et al.  Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.

[57]  J. Hancox,et al.  Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. , 2006, Journal of molecular and cellular cardiology.